Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic Analysis ASXSAT:GEAN -2.94%34 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates XSAT:GEAN with a GF Score™ of 34/100 and a GF Value™ of kr0.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, Genetic Analysis AS ranks worse than 1075267.74% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Genetic Analysis AS's
Operating Income
for the
three
months ended in Mar. 2026 was kr-4.23 Mil. Genetic Analysis AS's Interest Expense for the
three
months ended in Mar. 2026 was kr-0.89 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Genetic Analysis AS's Interest Coverage or its related term are showing as below:
XSAT:GEAN's Interest Coverage is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 9.05 * Ranked among companies with meaningful Interest Coverage only.
Genetic Analysis AS (XSAT:GEAN) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Genetic Analysis AS Interest Coverage Related Terms
Genetic Analysis AS Interest Coverage Historical Data
* Premium members only.
The historical data trend for Genetic Analysis AS's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XSAT:GEAN vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Genetic Analysis AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Genetic Analysis AS did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Genetic Analysis AS (XSAT:GEAN) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genetic Analysis AS and its competitors. According to the industry distribution chart, Genetic Analysis AS ranks #999999 out of 93 companies in the Medical Diagnostics & Research industry.
Is Genetic Analysis AS's Interest Coverage too high?
Genetic Analysis AS's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Genetic Analysis AS ranks #999999 out of 93 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Genetic Analysis AS has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Analysis AS ranks #999999 out of 93 companies for Interest Coverage. This places Genetic Analysis AS in the lower half of its industry. The industry median Interest Coverage is 9.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genetic Analysis AS and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Analysis AS's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Based on GuruFocus' analysis, Genetic Analysis AS (XSAT:GEAN) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.66 — trading 22.2% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Genetic Analysis AS (XSAT:GEAN), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of kr0.66 is trading 22.2% above its estimated GF Value™ of kr0.54.
GuruFocus considers Genetic Analysis AS to be Modestly Overvalued.
Key valuation signals for XSAT:GEAN:
Interest Coverage: 0 (At Loss)
GF Value™: kr0.54 vs. price of kr0.66 (22.2% above fair value)
No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score
Get the complete analysis for XSAT:GEAN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:GEAN has been successfully added to your 
